Fluctuating renal function and the risk of incident atrial fibrillation: a nationwide population-based study.
Soonil KwonSo-Ryoung LeeEue-Keun ChoiKyung-Do HanSeokhun YangSeo-Young LeeHyun-Jung LeeInki MoonEuijae LeeMyung-Jin ChaWoo-Hyun LimSeil OhGregory Yoke Hong LipPublished in: Scientific reports (2019)
Although chronic kidney disease is known to increase the risk of atrial fibrillation (AF), the impact of the variability of renal function on the risk of incident AF is unknown. We aimed to evaluate the association between variability of renal function and the risk of developing AF among the general population. We evaluated a total of 3,551,249 adults who had three annual health check-ups provided by the National Health Insurance Service. The variability of renal function was defined as GFR-VIM, which is variability independent of the mean (VIM) of creatinine-based estimated glomerular filtration rate (eGFR). The study population was divided into four groups (Q1-4) based on the quartiles of GFR-VIM, and the risks of incident AF by each group were compared. During a mean of 3.2 ± 0.5 years follow-up, incident AF occurred in 15,008 (0.42%) subjects. The incidence rates of AF increased from Q1 to Q4 (0.98, 1.42, 1.27, and 1.63 per 1,000 person-years, respectively). Adjusting with multiple variables, Q4 showed an increased risk of incident AF compared to Q1 (hazard ratio (HR) 1.125, 95% confidence interval (CI) 1.071-1.181). Variability of serum creatinine or other definitions of variability showed consistent results. On subgroup analyses, Q4 in males or those with a decreasing trend of eGFR had significantly increased risks of incident AF compared to Q1 (HR 1.127, 95% CI 1.082-1.175; and HR 1.115, 95% CI 1.059-1.173, respectively). High variability of eGFR was associated with an increased risk of incident AF, particularly in males or those with decreasing trends of eGFR during follow-up.
Keyphrases
- atrial fibrillation
- cardiovascular disease
- small cell lung cancer
- oral anticoagulants
- left atrial
- catheter ablation
- health insurance
- left atrial appendage
- direct oral anticoagulants
- epidermal growth factor receptor
- chronic kidney disease
- tyrosine kinase
- heart failure
- healthcare
- percutaneous coronary intervention
- mental health
- public health
- randomized controlled trial
- end stage renal disease
- uric acid
- quality improvement
- coronary artery disease
- cross sectional
- acute coronary syndrome
- health information
- climate change
- left ventricular
- type diabetes